LexaGene Reduces Time-to-Result by ~35%
10 August 2022 - 10:00PM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)
(“LexaGene” or the “Company”), a molecular diagnostics company that
has commercialized the MiQLab® System for automated PCR-based
syndromic testing in veterinary clinics, announces it has
significantly shortened the time the System needs to report a
result.
The MiQLab System is designed for in-clinic use,
requires less than a minute to initiate sample processing, and
returns results on the presence of 10 different pathogens and 33
markers for antimicrobial resistance. The microfluidic system
executes a complex series of scripts to complete three main tasks,
namely sample preparation (the process of purifying genetic
material from a complex sample), PCR reaction assembly, and PCR
amplification and reporting. Previously, these three tasks took 120
minutes to complete, and now can be completed in just 80
minutes.
Steve Armstrong, LexaGene’s Chief Operating
Officer stated, “LexaGene’s mission has been to provide the highest
quality data in the shortest time possible. Recent studies have
shown the MiQLab System to generate very high-quality data, so we
have now turned our attention to speeding up the System. My team
evaluated each of the three tasks and has increased some
efficiencies that have shaved ~40 minutes off the time required to
generate a result. We are completing some additional validation
tests before releasing these improvements to our customers, which
we anticipate will happen over the next 4-6 weeks.”
Dr. Jack Regan, Founder and CEO of LexaGene
stated, “We’ve heard from our customers about the importance of a
fast time-to-result. We are already in a different league from the
days it takes to receive culture results, but we wanted to push our
System even faster than it currently is. We are excited about these
advancements and will continue to push our System to report the
fastest test results possible without compromising data
integrity.”
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
About LexaGene Holdings
Inc.LexaGene is a molecular diagnostics company that has
commercialized the MiQLab® System for fast and easy detection of
pathogens and other molecular markers. The System is PCR-based,
screens for 24 targets at once, and is designed for on-site usage.
Our customers include veterinary hospitals and reference
laboratories – as well as contract biologic manufacturers. The
MiQLab System delivers excellent sensitivity, specificity, and
breadth of detection and returns results in approximately two
hours. The MiQLab System is also open-access, which allows
end-users to load their own PCR assays onto the System to target
any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking
information, which involves known and unknown risks, uncertainties
and other factors that may cause actual events to differ materially
from current expectation. Important factors -- including the
availability of funds, the results of financing efforts, the
success of technology development efforts, the cost to procure
critical parts, performance of the instrument, market acceptance of
the technology, regulatory acceptance, and licensing issues -- that
could cause actual results to differ materially from the Company's
expectations as disclosed in the Company's documents filed from
time to time on SEDAR (see www.sedar.com). Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
The company disclaims any intention or obligation, except to the
extent required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
For inquiries: 800.215.1824 | ir@lexagene.com or info@lexagene.com
Lexagene (TSXV:LXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Apr 2023 to Apr 2024